Judah Frommer
Stock Analyst at Morgan Stanley
(4.07)
# 558
Out of 5,182 analysts
187
Total ratings
66.43%
Success rate
5.99%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMMX Immix Biopharma | Initiates: Overweight | $20 | $9.26 | +115.98% | 1 | Mar 25, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $19 → $18 | $13.19 | +36.47% | 3 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Equal-Weight | $19 → $21 | $20.44 | +2.74% | 3 | Mar 17, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $18 → $17 | $8.80 | +93.18% | 4 | Mar 6, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $172.76 | +16.35% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $10.54 | +165.65% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $28.25 | +20.35% | 1 | Feb 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $126.14 | +14.95% | 4 | Jan 9, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $25.51 | +41.12% | 1 | Dec 1, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $40.79 | -36.26% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $32.24 | +33.37% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $28.40 | -22.54% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $9.81 | -38.84% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $114.83 | -7.69% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $21.12 | +65.72% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $1.95 | +53.85% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $0.80 | +4,885.67% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.47 | +426.32% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $34.33 | -33.00% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $68.69 | -27.21% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $21.18 | +565.72% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.64 | +147.25% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $34.76 | -36.71% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.83 | +44.93% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.55 | +5.96% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $75.27 | -38.89% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.17 | +222.58% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $15.38 | +257.61% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $154.81 | -70.29% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $89.00 | -44.94% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $998.47 | -62.94% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $91.42 | -66.09% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $72.82 | +4.37% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $115.73 | +57.26% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $99.55 | +7.48% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $89.91 | +5.66% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.28 | +4.17% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $217.37 | -46.63% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $92.71 | -59.01% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $77.17 | -71.49% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.99 | -48.52% | 9 | Apr 29, 2020 |
Immix Biopharma
Mar 25, 2026
Initiates: Overweight
Price Target: $20
Current: $9.26
Upside: +115.98%
Trevi Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $19 → $18
Current: $13.19
Upside: +36.47%
Zenas BioPharma
Mar 17, 2026
Maintains: Equal-Weight
Price Target: $19 → $21
Current: $20.44
Upside: +2.74%
REGENXBIO
Mar 6, 2026
Maintains: Overweight
Price Target: $18 → $17
Current: $8.80
Upside: +93.18%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $172.76
Upside: +16.35%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $10.54
Upside: +165.65%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $28.25
Upside: +20.35%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $126.14
Upside: +14.95%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $25.51
Upside: +41.12%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $40.79
Upside: -36.26%
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $32.24
Upside: +33.37%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $28.40
Upside: -22.54%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $9.81
Upside: -38.84%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $114.83
Upside: -7.69%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $21.12
Upside: +65.72%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.95
Upside: +53.85%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $0.80
Upside: +4,885.67%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.47
Upside: +426.32%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $34.33
Upside: -33.00%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $68.69
Upside: -27.21%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $21.18
Upside: +565.72%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.64
Upside: +147.25%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $34.76
Upside: -36.71%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.83
Upside: +44.93%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.55
Upside: +5.96%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $75.27
Upside: -38.89%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.17
Upside: +222.58%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $15.38
Upside: +257.61%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $154.81
Upside: -70.29%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $89.00
Upside: -44.94%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $998.47
Upside: -62.94%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $91.42
Upside: -66.09%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $72.82
Upside: +4.37%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $115.73
Upside: +57.26%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $99.55
Upside: +7.48%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $89.91
Upside: +5.66%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.28
Upside: +4.17%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $217.37
Upside: -46.63%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $92.71
Upside: -59.01%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $77.17
Upside: -71.49%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.99
Upside: -48.52%